GSK made £1.4bn from Covid-related medicines last year, beating forecasts in its first financial results since rejecting Unilever’s £50bn buyout offer in December, as the chief executive, Emma Walmsley, pledged a “step-change in growth” in a landmark year.
The company is under the spotlight after promising to raise billions by spinning out its consumer arm, whose over-the-counter brands include Nicorette, Panadol and Aquafresh, in a London stock market listing this summer.
